Note: for more in-depth information about each priority on the NBCC website.
Breast cancer is a not only an issue for all of us to be concerned and affected in some way, it is also a highly political issue. The federal government is the largest funder of biomedical research. Laws regulate and support access to care and health care systems. Third party payers are subject to state and federal regulations. In fact, every aspect of breast cancer is touched by public policy. It is key that those who influence that policy are educated and trained and have no agenda other than to save lives, and to end breast cancer.
PRIORITY #1 Accelerating the End of Breast Cancer Act: In September 2010, NBCC set a deadline and launched a plan of action to reach its mission: Breast Cancer Deadline 2020® – knowing how to end breast cancer by January 1, 2020. The "Accelerating the End of Breast Cancer Act," first introduced in the 112th Congress, defines an important role the federal government must play in this effort. The legislation complements and enhances the strategic work being done by NBCC to end breast cancer once and for all.
PRIORITY #2 $150 Million for the Department of Defense (DOD) Breast Cancer Research Program (BCRP) for FY2016: As a result of NBCC’s grassroots advocacy, the DOD BCRP was created in 1992 to "eradicate breast cancer by funding innovative, high-impact research through a partnership of scientists and consumers." NBCC seeks continued funding for this successful program.
PRIORITY #3 Guaranteed Access to Quality Care for All: Ensuring access to quality, evidence-based health care has been a top priority of NBCC for many years and is an essential component of the Breast Cancer Deadline 2020® goal of ending breast cancer.
NBCC works to identify, advocate for, and support the implementation of laws such as the "Patient Protection and Affordable Care Act" which mark important steps forward in access to quality health care for individuals with, and at risk of, breast cancer.
In addition, NBCC remains committed to protecting vital existing programs such as the Medicaid Breast and Cervical Cancer Treatment Program (Medicaid BCCTP) and critically examining any proposed changes to programs such as Medicare in order to determine the impact they would have on this population.
PRIORITY #4 Ensuring the Participation of Educated Patient Advocates in all Levels of Health Care Decision Making: NBCC continues to work to ensure that educated patient advocates have a "seat at the table" in all levels of health care decision making which affects their lives.
NBCC's Clinical Trials Partnerships Upcoming Clinical Trials for Women with Metastatic Breast Cancer
NBCC is currently partnering with BioMarin and Pfizer on three upcoming clinical trials for women with metastatic breast cancer. Intervention offers the potential of improving the length and quality of life for patients already diagnosed with metastatic breast cancer. Trial accrual has begun for all three studies.
NBCC advocates have been involved in many ways on these trials in the development of the protocols, as members of the Data Safety Monitoring Board, as reviewers of educational materials and consent forms and in conducting outreach activities to educate the public about the trials.
Eligibility: Women with HR+/HER2- locally advanced or metastatic breast cancer who progressed on or after prior endocrine therapy. Other eligibility criteria and trial details can be found at:
NBCC is recruiting advocates to help educate the public and potential participants about these trials. If you are interested in helping NBCC's outreach effort for any of these trials, please contact NBCC at firstname.lastname@example.org.
SLBCC is a member organization of the National Breast Cancer Coalition (NBCC), headquartered in Washington, D.C., which has grown to more than 600 member organizations across the country.